NCT-504

Research use only, not for human use.

NCT-504, a selective allosteric inhibitor of PIP4Kγ, exhibits an IC50 value of 15.8 μM. It holds promise for the investigation of Huntington's disease.

NCT-504 is a selective allosteric inhibitor of PIP4Kγ, with an IC50 of 15.8 μM. NCT-504 is potential for the research of Huntington's disease.

NCT-504 dose not impair the intrinsic ATP-hydrolytic activity of PIP4Kγ in the absence of PI5P substrate.NCT-504 does not inhibit PIP4Kbeta and weakly inhibits PIP4Kalpha phosphorylation of PI5P .NCT-504 dose not inhibit PIP4Kbeta or PIP4Kalpha (IC50 between 50 μM and 100 μM) at 50 μM concentration.NCT-504 elevates the levels of PI(3,5)P2, PI3P and PI5P in MEFs.NCT-504 (10 μM; 12 hours) does not affect cell viability in MEFs.NCT-504 (5 μM, 10 μM; 2 hours, 6 hours) elevates both the induction of autophagy as well as the rate of turnover of autophagic cargo.NCT-504 treatment causes a robust increase in the formation of autolysosomes with only a modest elevation in autophagosomes.NCT-504 increases autophagy flux and decreases huntingtin protein in 293A cells.NCT-504 reduces mHtt protein levels in immortalized striatal cells from knock-in HD mice.Western Blot Analysis Cell Line:HEK293T cells Concentration:5 μM, 10 μM Incubation Time:2 hours, 6 hours Result:Induced autophagosome formation.

——

——

Others

Other Targets

Others

——

——

1222765-97-0

404.49

C15H12N6O2S3

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (309.03 mM; Ultrasonic )

Cn1nnnc1Sc1ncnc2scc(-c3cccc(c3)S(C)(=O)=O)c12

——

(-20℃)

With Ice Pack

≥ 2 years